4-hydroxy-3-Methoxyamphetamine (hydrochloride)
(Synonyms: HMA, NSC 172191) 目录号 : GC42416An Analytical Reference Standard
Cas No.:13062-61-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3,4-MDMA, also known as ecstasy, is a euphoric entactogen which is illegal in most countries and is regulated (Schedule I) in the United States. HMA, known more formally as 4-hydroxy-3-methoxyamphetamine, is a metabolite of 3,4-MDMA. It is typically glucuronidated or sulfated before excretion and detected in urine after cleavage, although intact forms may also be measured. This product is intended for forensic and research purposes.
Cas No. | 13062-61-8 | SDF | |
别名 | HMA, NSC 172191 | ||
Canonical SMILES | COC1=C(O)C=CC(CC(C)N)=C1.Cl | ||
分子式 | C10H15NO2•HCl | 分子量 | 217.7 |
溶解度 | DMF: 0.16 mg/ml,DMSO: 10 mg/ml,PBS (pH 7.2): 5 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.5935 mL | 22.9674 mL | 45.9348 mL |
5 mM | 0.9187 mL | 4.5935 mL | 9.187 mL |
10 mM | 0.4593 mL | 2.2967 mL | 4.5935 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans
J Chromatogr B Biomed Sci Appl 2001 Feb 10;751(1):9-18.PMID:11232860DOI:10.1016/s0378-4347(00)00404-7.
A chiral HPLC method has been developed for the ecstasy analogue (R,S)-N-ethyl-3,4-methylenedioxyamphetamine (MDE) and its metabolites o-glucuronyl-(R,S)-N-ethyl-4-hydroxy-3-methoxyamphetamine (HME) and (R,S)-3,4-methylenedioxyamphetamine (MDA) in human plasma. The chiral discrimination of the compounds was carried out with an enantioselective HPLC method using beta-cyclodextrin in the mobile phase for MDE and MDA and a chiral protein phase (chiral-CBH) for HME. MDE and MDA were detected fluorimetrically at 322 nm, while the major metabolite HME was selectively determined by electrochemical detection at +600 mV. After hydrolysis of the conjugates using beta-glucuronidase/arylsulfatase and solid-phase extraction with a cation-exchange phase for sample preparation high recovery rates of more than 95% were yielded. The limit of quantitation for the enantiomers of MDE and its metabolites in plasma were between 1.2 (MDA) and 16 ng/ml (HME) and the relative method standard deviations (V(xO), Table 1) were less than 3%. The methods described have been used successfully in the enantioselective quantitation of the compounds in plasma samples obtained from six healthy volunteers in a clinical study after oral administration of 140 mg racemic MDE hydrochloride. Significant differences were found in the plasma concentrations of the examined stereoisomers. Whereas the R-enantiomer of the parent substance, MDE, was predominant in the plasma samples investigated, higher plasma concentrations of the S-enantiomers of the metabolites MDA and HME were measured.